Vogenx Inc’s Quiet Period To End on September 21st (NASDAQ:VOGX)

Vogenx’s (NASDAQ:VOGX) quiet period is set to end on Monday, September 21st. Vogenx had issued 6,250,000 shares in its public offering on August 12th. The total size of the offering was $81,250,000 based on an initial share price of $13.00. During Vogenx’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on VOGX. JonesTrading started coverage on Vogenx in a research note on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective for the company. WBB Securities started coverage on shares of Vogenx in a research note on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 target price on the stock. Finally, Wall Street Zen raised shares of Vogenx to a “hold” rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Strong Buy” and an average target price of $48.50.

Vogenx Stock Down 0.6%

Shares of VOGX stock opened at $32.21 on Wednesday. Vogenx has a 52-week low of $12.95 and a 52-week high of $35.50.

About Vogenx

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.